Comparability Protocol Requirements for FDA CMC Changes

A comparability protocol with the FDA is a pre-approved plan that lets a drug or biologic manufacturer implement certain post-approval manufacturing changes through a faster reporting pathway than a full Prior Approval Supplement. The manufacturer proposes specific tests, studies, and pass/fail criteria up front, and if the FDA agrees, future changes that meet those criteria can be reported through a reduced category. The FDA finalized its current guidance in October 2022, and it applies to products regulated under New Drug Applications, Abbreviated New Drug Applications, and Biologics License Applications.

What the Protocol Can Cover

Federal regulations sort post-approval manufacturing changes into three tiers based on their risk to product quality. Substantial-risk changes need a Prior Approval Supplement. Moderate-risk changes go through a Changes Being Effected supplement filed at least 30 days before distribution. Minimal-risk changes are noted in the next annual report.

A comparability protocol sits across those tiers. Under 21 CFR 314.70(e) for drugs, a manufacturer can submit one or more protocols describing tests and acceptance criteria that demonstrate a proposed change will not harm the product’s quality or safety profile. If approved, the protocol justifies dropping that change to a lower reporting category, because the pre-agreed testing plan reduces the overall risk.¹ The parallel provision for biologics is 21 CFR 601.12(e), which requires the protocol to include specific tests, validation studies, and acceptable limits.²

Protocols work well for changes like relocating production to a different facility, upgrading to automated fill-and-finish equipment, switching a drug substance supplier, or modifying an analytical method. These are adjustments where a well-designed testing plan can reliably confirm the product hasn’t shifted in any meaningful way.³

Changes That Do Not Qualify

Not every manufacturing change fits this pathway. The FDA discourages protocols for changes where the risk to product quality is too high or too uncertain to be captured by predetermined acceptance criteria. Changes that would need supporting data from nonclinical safety studies, pharmacokinetic or pharmacodynamic studies, or clinical trials fall outside the scope. Switching to an entirely different dosage form or changing a product’s route of administration are common examples the agency considers too complex.³

The FDA also does not recommend a comparability protocol for switching to a drug substance supplier that has never supplied material for any FDA-approved product. That scenario carries too many unknowns about the supplier’s methods and facility controls for a pre-set testing plan to address.⁴

What to Include in the Submission

The heart of any comparability protocol is the testing plan. The submission must describe every proposed change in enough detail for the FDA to understand what will be modified and how the manufacturer will confirm the product remains equivalent. That means spelling out the scientific rationale for each change, identifying the manufacturing steps or analytical methods affected, and providing a side-by-side comparison of the current process and the proposed one.

Each change needs a defined set of tests with predetermined acceptance criteria. These typically include stability studies, impurity profiling, and potency assays. Methods must be validated and sensitive enough to detect meaningful differences. The protocol also needs a data comparison plan describing the statistical approach, the number of batches to be tested, and the timeframe for collecting stability data.

One detail catches manufacturers out: the protocol must also explain what happens if results fall outside the acceptance criteria. A plan for handling deviations or unexpected outcomes is required, not optional. The FDA expects the entire decision tree mapped out in advance, including what the manufacturer will do if a test fails.

Extra Requirements for Biological Products

Biologics are more sensitive to manufacturing changes than small-molecule drugs, and their protocols carry additional documentation requirements. Under the framework in ICH Q5E, manufacturers must show that the modified process maintains the same level of control over product quality, including the ability to clear adventitious agents such as viruses. The protocol should address bioburden testing, viral safety evaluation of post-change cell banks, and adventitious agent clearance studies. The goal is showing pre-change and post-change products are “highly similar” and that any quality attribute differences do not affect safety or efficacy.⁵

Cross-Referencing Drug Master Files

When a proposed change involves a new supplier of drug substance, excipients, or container-closure components, the protocol can cross-reference a Drug Master File held by that supplier. It must identify the information incorporated by reference and include the tests, studies, and acceptance criteria that will demonstrate the new material is suitable. When the manufacturer later reports the change, the submission must include the DMF holder’s letter authorizing the FDA to reference the file. Without that authorization letter, the FDA considers the notification incomplete.⁴ The manufacturer remains responsible for confirming that the DMF holder’s methods, facilities, and controls comply with current good manufacturing practice. The protocol doesn’t shift that accountability to the supplier.

How to File and How Long Review Takes

A comparability protocol can reach the FDA in two ways. It can be included as part of an original NDA, ANDA, or BLA at initial approval, or it can be submitted later as a standalone Prior Approval Supplement to an already-approved application.³ Either way, the FDA must approve the protocol before the manufacturer can implement any changes under its provisions and distribute product made with those changes.¹

The FDA recommends submitting comparability protocols in eCTD section 3.2.R.⁶ During review, the agency may request additional information if the proposed studies or acceptance criteria lack sufficient detail. If the plan is acceptable, the agency issues an approval letter authorizing the protocol for future use.

Because protocols are filed as Prior Approval Supplements, PAS review timelines apply. Under the PDUFA VII performance goals covering fiscal years 2023 through 2027, the FDA targets review and action on 90 percent of manufacturing supplements requiring prior approval within four months of receipt.⁷

For generics, the timelines run longer. Under GDUFA III, the agency targets six months for standard Prior Approval Supplements when no preapproval inspection is needed, and ten months when an inspection is required. Priority supplements have a four-month target without inspection or eight months with one, provided the applicant submits facility correspondence at least 60 days before the supplement filing date.⁸

How an Approved Protocol Reduces the Reporting Burden

This is the real payoff. The standard framework for post-approval changes requires manufacturers to wait for FDA clearance before distributing product made with major changes. An approved protocol moves that change to a less burdensome reporting category, saving months.

The FDA’s guidance sets the reduction logic simply. A change that would normally require a Prior Approval Supplement typically drops to a CBE-30 or CBE-0 supplement under an approved protocol. A change that would normally require a CBE supplement drops to an annual report.³ What each of those means in practice:

Under CBE-30, the manufacturer files a supplement and can distribute product 30 days later unless the FDA objects.
Under CBE-0, the manufacturer files a supplement and can distribute immediately upon FDA receipt.
Under an annual report, the manufacturer documents the change in the next scheduled annual report with no separate supplement.⁹

The specific category for each change is locked in when the FDA approves the protocol, based on the risk level and the robustness of the proposed testing plan. To use the reduced pathway, the manufacturer must follow the approved plan exactly and confirm every result meets the pre-established criteria. There is no flexibility to deviate and still claim the reporting reduction.

Amending an Approved Protocol

Manufacturing needs evolve, and an approved protocol may need updates. The default rule under both 21 CFR 314.70(e) and 601.12(e) is that any modification to an approved comparability protocol must be submitted as a Prior Approval Supplement.¹ The FDA’s 2022 guidance carves out less burdensome pathways for modifications that stay within the original scope.

Modifications that maintain the same level of quality assurance fall into CBE-30. These include replacing a test with an equivalent one or adjusting an acceptance criterion that provides comparable confidence. Modifications that actually increase quality assurance, such as adding a characterization test or upgrading an analytical method, qualify for CBE-0 filing with immediate distribution. Minor updates like tightening acceptance criteria, conforming to an official compendium, or making editorial corrections can go in the annual report.³ Modifications outside the original scope, such as covering a fundamentally different type of change, still require a full Prior Approval Supplement.

When Results Miss the Acceptance Criteria

If the data generated during implementation don’t meet the pre-established acceptance criteria, the manufacturer cannot distribute product made with the change and cannot use the reduced reporting pathway. The manufacturer must include a statement in the next annual report confirming the change was not implemented under the protocol. To pursue the change anyway, the next step is contacting the relevant FDA review division to discuss a path forward, which will typically mean submitting a standard Prior Approval Supplement with whatever additional data the agency requires.⁹

Careful protocol design matters here. Set the acceptance criteria too tight and legitimate changes fail unnecessarily. Set them too loose and the FDA won’t approve the protocol in the first place. Getting the calibration right during the initial submission saves significant time and cost later.

Alignment With ICH Q12 and PACMP

Manufacturers operating globally should know that the FDA’s comparability protocol framework aligns with the international standard in ICH Q12. Under that guideline, the equivalent tool is called a Post-Approval Change Management Protocol. Within the FDA’s regulatory system, the two terms refer to the same thing.¹⁰

Both approaches share the same core features. They allow agreement with the regulator on how future changes will be evaluated, they can justify a reduced reporting category, and they require pre-specified tests and acceptance criteria. The key concept ICH Q12 adds is “Established Conditions,” meaning the elements of the manufacturing process and controls that, if changed, require regulatory notification. A comparability protocol defines the tests and studies needed to support a future change to those established conditions.⁶ For companies filing in multiple regions, a PACMP framework can align the change management strategy across regulatory authorities.

1
eCFR. 21 CFR 314.70 – Supplements and Other Changes to an Approved NDA
2
eCFR. 21 CFR 601.12 – Changes to an Approved Application
3
Food and Drug Administration. Comparability Protocols for Postapproval Changes to the Chemistry, Manufacturing, and Controls Information in an NDA, ANDA, or BLA
4
U.S. Food and Drug Administration. Comparability Protocols for Postapproval Changes to the Chemistry, Manufacturing, and Controls Information in an NDA, ANDA, or BLA
5
European Medicines Agency. ICH Q5E – Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process
6
Food and Drug Administration. ICH Q12 – Implementation Considerations for FDA-Regulated Products
7
U.S. Food and Drug Administration. PDUFA Reauthorization Performance Goals and Procedures Fiscal Years 2023 Through 2027
8
Food and Drug Administration. GDUFA Reauthorization Performance Goals and Program Enhancements Fiscal Years 2023-2027
9
Food and Drug Administration. Comparability Protocols for Human Drugs and Biologics – Chemistry, Manufacturing, and Controls Information Guidance for Industry
10
U.S. Food and Drug Administration. ICH Q12 – What Industry Needs to Know